 Osteoprotegerin
"Osteoprotegerin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.
| Descriptor ID |
D053244
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.949.249
|
| Concept/Terms |
Osteoprotegerin- Osteoprotegerin
- Osteoclastogenesis Inhibitory Factor
- Receptors, Tumor Necrosis Factor, Member 11b
- Follicular Dendritic Cell-Derived Receptor-1
- Follicular Dendritic Cell Derived Receptor 1
- Tumor Necrosis Factor Receptor Superfamily, Member 11b
- FDCR-1 Protein
- FDCR 1 Protein
- OCIF Protein
- Tumor Necrosis Factor Receptor 11b
|
Below are MeSH descriptors whose meaning is more general than "Osteoprotegerin".
Below are MeSH descriptors whose meaning is more specific than "Osteoprotegerin".
This graph shows the total number of publications written about "Osteoprotegerin" by people in UAMS Profiles by year, and whether "Osteoprotegerin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 | | 2020 | 1 | 0 | 1 | | 2016 | 1 | 3 | 4 | | 2014 | 0 | 1 | 1 | | 2013 | 0 | 2 | 2 | | 2012 | 1 | 0 | 1 | | 2011 | 1 | 2 | 3 | | 2010 | 1 | 2 | 3 | | 2009 | 0 | 2 | 2 | | 2008 | 2 | 0 | 2 | | 2006 | 0 | 2 | 2 | | 2005 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Osteoprotegerin" by people in Profiles over the past ten years.
-
Fu Q, Bustamante-Gomez NC, Reyes-Pardo H, Gubrij I, Escalona-Vargas D, Thostenson JD, Palmieri M, Goellner JJ, Nookaew I, Barnes CL, Stambough JB, Ambrogini E, O'Brien CA. Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation. JCI Insight. 2023 09 22; 8(18).
-
Cawley KM, Bustamante-Gomez NC, Guha AG, MacLeod RS, Xiong J, Gubrij I, Liu Y, Mulkey R, Palmieri M, Thostenson JD, Goellner JJ, O'Brien CA. Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption. Cell Rep. 2020 09 08; 32(10):108052.
-
Iyer S, Han L, Ambrogini E, Yavropoulou M, Fowlkes J, Manolagas SC, Almeida M. Deletion of FoxO1, 3, and 4 in Osteoblast Progenitors Attenuates the Loss of Cancellous Bone Mass in a Mouse Model of Type 1 Diabetes. J Bone Miner Res. 2017 01; 32(1):60-69.
-
Piemontese M, Xiong J, Fujiwara Y, Thostenson JD, O'Brien CA. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. Am J Physiol Endocrinol Metab. 2016 09 01; 311(3):E587-93.
-
Pellegrini GG, Morales CC, Wallace TC, Plotkin LI, Bellido T. Avenanthramides Prevent Osteoblast and Osteocyte Apoptosis and Induce Osteoclast Apoptosis in Vitro in an Nrf2-Independent Manner. Nutrients. 2016 Jul 11; 8(7).
-
Sato AY, Cregor M, Delgado-Calle J, Condon KW, Allen MR, Peacock M, Plotkin LI, Bellido T. Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin. J Bone Miner Res. 2016 10; 31(10):1791-1802.
-
Jilka RL, O'Brien CA. The Role of Osteocytes in Age-Related Bone Loss. Curr Osteoporos Rep. 2016 Feb; 14(1):16-25.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|